Cd8 buv395 rpa t8

Manufactured by BD

The CD8-BUV395 (RPA-T8) is a fluorochrome-conjugated antibody that targets the CD8 molecule, which is expressed on the surface of cytotoxic T cells. This product is intended for use in flow cytometry applications to identify and analyze CD8+ T cell populations.

Automatically generated - may contain errors

Lab products found in correlation

Lsr 2, by BD (2 mentions) Quantibrite beads, by BD (2 mentions) Cd4 bv605 rpa t4, by BD (2 mentions) Cd3 apc sp34 2, by BD (2 mentions) Fgfr4 pe 4fr6d3, by BioLegend (2 mentions) Cd19 pe hib19, by BioLegend (2 mentions) Pdl1 apc mih1, by BD (2 mentions) Pdl2 bv421 mih18, by BD (2 mentions) Pe conjugated anti human fc antibody, by Miltenyi Biotec (2 mentions) Biorad ze5 flow cytometers, by Bio-Rad (1 mentions) Cd4 pe cy5.5 rm4 5, by Thermo Fisher Scientific (1 mentions) Cytofix cytoperm kit, by BD (1 mentions) Cd3 apc cy7 okt3, by BioLegend (1 mentions)

Spelling variants of this product

RPA-T8 (53 citations) CD8-BUV395 (11 citations) CD8-BUV395 (clone RPA-T8, (5 citations) BUV395-anti-CD8 (clone RPA-T8, (5 citations) BUV395-conjugated anti-CD8 (clone RPA-T8, (3 citations)

3 protocols using cd8 buv395 rpa t8

Quantifying Cell Surface Antigens by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

Samples were processed into single cell suspensions and stained in FACS buffer (PBS + 2% FBS + 0.1% sodium Azide) with antibody for 45 minutes on ice followed by secondary (APC- or PE-conjugated streptavidin) binding for 20 minutes. Antibodies used were CD8-BUV395 (RPA-T8, BD Biosciences), CD4-Bv605 (RPA-T4, BD Biosciences), CD3-APC (SP34–2, BD Biosciences), FGFR4-PE (4FR6D3, BioLegend), CD19-PE (HIB19, Biolegend), PDL1-APC (MIH1, BD Bioscience), and PDL2-Bv421 (MIH18, BD Biosciences). Surface CAR was detected using biotinylated CD19 with Fc-tag (Acro Bio) or biotinylated FGFR4-Fc (Sino Bio). For evaluation of FGFR4 binders identified from phage screening, 500 nmol/L VH or Fab proteins were incubated with cells at 4°C for 30 minutes followed by PE-conjugated anti-human Fc antibody (Miltenyi Biotec, 130–101–576) for 30 minutes at 4°C. Cells were then analyzed by flow cytometry using BD LSR II. Tumor cell surface antigen was quantified using Quanti-Brite beads (BD Biosciences) according to the manufacturer's instructions. Quantibrite beads and corresponding tumor cells stained for FGFR4 antigen were acquired on a BD LSRII and analyzed using GraphPad Prism. Data were analyzed by FlowJo V10.

Sullivan P.M., Kumar R., Li W., Hoglund V., Wang L., Zhang Y., Shi M., Beak D., Cheuk A., Jensen M.C., Khan J., Dimitrov D.S, & Orentas R.J. (2022). FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma. Molecular Cancer Therapeutics, 21(10), 1608-1621.

+ Open protocol

+ Expand

Quantification of Cell Surface Antigens

Check if the same lab product or an alternative is used in the 5 most similar protocols

Samples were processed into single cell suspensions and stained in FACS buffer (PBS + 2% FBS + 0.1% sodium Azide) with antibody for 45 minutes on ice followed by secondary (APC- or PE-conjugated streptavidin) binding for 20 minutes. Antibodies used were CD8-BUV395 (RPA-T8, BD Biosciences), CD4-Bv605 (RPA-T4, BD Biosciences), CD3-APC (SP34–2, BD Biosciences), FGFR4-PE (4FR6D3, Biolegend), CD19-PE (HIB19, Biolegend), PDL1-APC (MIH1, BD Bioscience), PDL2-Bv421 (MIH18, BD Biosciences). Surface CAR was detected using biotinylated CD19 with Fc-tag (Acro Bio) or biotinylated FGFR4-Fc (Sino Bio). For evaluation of FGFR4 binders identified from phage screening, 500 nM VH or Fab proteins were incubated with cells at 4 °C for 30 minutes followed by PE conjugated anti-human Fc antibody (Miltenyi Biotec, 130–101-576) for 30 minutes at 4 °C. Cells were then analyzed by flow cytometry using BD LSR II (San Jose, CA). Tumor cell surface antigen was quantified using Quanti-Brite beads (BD Biosciences) according to the manufacturer’s instructions. Quantibrite beads and corresponding tumor cells stained for FGFR4 antigen were acquired on a BD LSRII and analysed using Graphpad Prism. Data were analyzed by FlowJo V10.

+ Open protocol

+ Expand

Multiparametric flow cytometry analysis of cytotoxic lymphocyte subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols

Mixed cell suspensions were stained for surface markers with combinations of the following antibodies: CD45-AF700 (HI30, Cat # 304024, BioLegend), CD3-APC/Cy7 (OKT3, Cat # 317342, BioLegend), CD103-BV711 (Ber-ACT8, Cat # 350222, BioLegend), CD4-PE/Cy5.5 (RM4–5, Cat # 350042, eBioscience, San Diego, CA), CD8-BUV395 (RPA-T8, Cat # 563795, BD Biosciences). Following surface staining, cells were fixed and permeabilized with Cytofix/cytoperm kit (BD Biosciences) according to instructions to detect perforin, granzyme A and B cells. Intracellular staining of perforin, granzyme A and B was done using combinations of the following antibodies: anti-human Perforin-PE/Dazzle 594 (dG9, Cat # 308132, BioLegend), Granzyme A-AF647 (CB9, Cat # 507214, BioLegend) and Granzyme B-BV421 (GB11, Cat # 563389, BD Biosciences). Analysis was performed on BioRad ZE5 flow cytometers (Bio-Rad, Hercules, CA) using Everest software, and data analyzed with FlowJo software (Tree Star, Inc. Ashland, OR). Expression of intracellular markers was measured by the percentage of positive cells. The gating strategy used for the expression of intracellular perforin, granzyme A and B analysis can be found in Supplementary Fig. 4.

Shen Z., Patel M.V., Rodriguez-Garcia M, & Wira C.R. (2022). Aging beyond menopause selectively decreases CD8+ T cell numbers but enhances cytotoxic activity in the human endometrium. Immunity & Ageing : I & A, 19, 55.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!